Jaypirca Demonstrates Superior Efficacy Over Imbruvica in BTK Inhibitor Clash for CLL/SLL

Jaypirca (pirtobrutinib) achieved a higher overall response rate (ORR) than Imbruvica (ibrutinib) in the phase 3 BRUIN CLL-314 trial for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); the difference reached nominal statistical significance (p<0.05)13.

The trial is the first-ever head-to-head phase 3 study to compare covalent BTK inhibitors (Jaypirca vs Imbruvica) and included both newly diagnosed and previously treated patients13.

Progression-free survival (PFS) data are still maturing, but early results indicate a positive trend for Jaypirca, particularly in treatment-naïve patients, with a notably longer PFS seen in the subgroup with the longest follow-up13.

These findings from BRUIN CLL-314 support the potential for Jaypirca’s broader regulatory approval in CLL/SLL, expanding beyond its current accelerated indication as a post-BTK and post-BCL2 treatment23.

Results bolster Jaypirca’s profile as an upstart BTK inhibitor capable of measuring up to established therapies like Imbruvica in both efficacy and early disease control outcomes13.

Sources:

1. https://www.curetoday.com/view/jaypirca-shows-improvements-over-imbruvica-in-cll-sll

2. https://www.fiercepharma.com/pharma/eli-lilly-touts-novel-btk-trial-win-jaypirca-execs-defend-survival-data-smudge

3. https://www.appliedclinicaltrialsonline.com/view/jaypirca-strong-efficacy-treating-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma